FindTrial
Sign In

Adebrelimab (PD-L1 inhibitor)

DRUG6 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sizhen Wang, Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Conditions

Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)ESCCHR Positive/HER2 Low Breast CancerNasopharangeal CancerNasopharyngeal Cancinoma (NPC)Pancreatic Cancer MetastaticSmall Cell Lung Cancer (SCLC)

Phase 2

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer
Not yet recruitingNCT06842472
Cancer Institute and Hospital, Chinese Academy of Medical SciencesBreast Cancer
Start: 2025-02-28End: 2029-12-31Target: 70Updated: 2025-02-24
Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions
Not yet recruitingNCT07230301
Sizhen WangPancreatic Cancer Metastatic
Start: 2025-11-30End: 2028-06-30Target: 20Updated: 2025-11-17
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Not yet recruitingNCT07317778
Cancer Institute and Hospital, Chinese Academy of Medical SciencesBreast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer
Start: 2026-02-15End: 2033-09-15Target: 249Updated: 2026-01-05

Phase 3

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
Not yet recruitingNCT07238569
Sun Yat-sen UniversityNasopharangeal Cancer, Nasopharyngeal Cancinoma (NPC)
Start: 2025-12-01End: 2031-05-23Target: 516Updated: 2025-11-20

Unknown Phase

Adebrelimab Neoadjuvant Treatment for Resectable ESCC
Not yet recruitingNCT07388095
Tianjin Medical University Cancer Institute and HospitalESCC
Start: 2026-02-15End: 2028-02-28Target: 22Updated: 2026-02-04
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
RecruitingNCT07434518
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSmall Cell Lung Cancer (SCLC)
Start: 2026-01-27End: 2028-06-30Target: 500Updated: 2026-02-25